Safety and efficacy of “on-demand” tramadol in patients with premature ejaculation: an updated meta-analysis

Detalhes bibliográficos
Autor(a) principal: Sharma,Aditya Prakash
Data de Publicação: 2021
Outros Autores: Sharma,Gopal, Tyagi,Shantanu, Devana,Sudheer K., Mavuduru,Ravimohan S., Bora,Girdhar S., Singh,Shrawan K.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: International Braz J Urol (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382021000500921
Resumo: ABSTRACT Introduction: Tramadol has been used for the treatment of premature ejaculation, however, the studies published for the same are not well designed. The primary objective of this study was to explore the literature pertaining to the use of tramadol in patients with PE to determine its safety and efficacy in this population. Materials ande methods: Systematic literature search of various electronic databases was conducted to include all the randomized studies and quasi-randomized studies. Standard PRISMA (Preferred reporting Items for Systematic reviews and Meta-analysis) guidelines were pursued for this review and study protocol was registered with PROSPERO (CRD42019123381). Results: Out of 9 studies included in this review, 5 were randomized controlled trials, and rests of the 4 studies were quasi-randomized studies. Tramadol resulted in significantly higher improvement of IELT with the mean difference (MD) of 139.6 seconds and confidence interval (CI) 106.5-172.6 seconds with a p-value of p <0.00001. All dosages except 25mg fared well as compared to placebo. Tramadol fared better than placebo at 1 month, 2 months, and 3 months after initiation of therapy as compared to the placebo. Tramadol group had reported a significantly higher number of adverse events with treatment as compared to placebo but none of them were serious. Conclusion: Tramadol appears to be an effective drug for the management of PE with a low propensity for serious adverse events. However, evidence obtained from this study is of low to moderate quality. Furthermore, effective dose and duration of therapy remain elusive.
id SBU-1_01114680eb0ffc4e2712a1e273741cd5
oai_identifier_str oai:scielo:S1677-55382021000500921
network_acronym_str SBU-1
network_name_str International Braz J Urol (Online)
repository_id_str
spelling Safety and efficacy of “on-demand” tramadol in patients with premature ejaculation: an updated meta-analysisTramadolPremature EjaculationSystematic Reviews as TopicABSTRACT Introduction: Tramadol has been used for the treatment of premature ejaculation, however, the studies published for the same are not well designed. The primary objective of this study was to explore the literature pertaining to the use of tramadol in patients with PE to determine its safety and efficacy in this population. Materials ande methods: Systematic literature search of various electronic databases was conducted to include all the randomized studies and quasi-randomized studies. Standard PRISMA (Preferred reporting Items for Systematic reviews and Meta-analysis) guidelines were pursued for this review and study protocol was registered with PROSPERO (CRD42019123381). Results: Out of 9 studies included in this review, 5 were randomized controlled trials, and rests of the 4 studies were quasi-randomized studies. Tramadol resulted in significantly higher improvement of IELT with the mean difference (MD) of 139.6 seconds and confidence interval (CI) 106.5-172.6 seconds with a p-value of p <0.00001. All dosages except 25mg fared well as compared to placebo. Tramadol fared better than placebo at 1 month, 2 months, and 3 months after initiation of therapy as compared to the placebo. Tramadol group had reported a significantly higher number of adverse events with treatment as compared to placebo but none of them were serious. Conclusion: Tramadol appears to be an effective drug for the management of PE with a low propensity for serious adverse events. However, evidence obtained from this study is of low to moderate quality. Furthermore, effective dose and duration of therapy remain elusive.Sociedade Brasileira de Urologia2021-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382021000500921International braz j urol v.47 n.5 2021reponame:International Braz J Urol (Online)instname:Sociedade Brasileira de Urologia (SBU)instacron:SBU10.1590/s1677-5538.ibju.2020.0561info:eu-repo/semantics/openAccessSharma,Aditya PrakashSharma,GopalTyagi,ShantanuDevana,Sudheer K.Mavuduru,Ravimohan S.Bora,Girdhar S.Singh,Shrawan K.eng2021-07-27T00:00:00Zoai:scielo:S1677-55382021000500921Revistahttp://www.brazjurol.com.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||brazjurol@brazjurol.com.br1677-61191677-5538opendoar:2021-07-27T00:00International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)false
dc.title.none.fl_str_mv Safety and efficacy of “on-demand” tramadol in patients with premature ejaculation: an updated meta-analysis
title Safety and efficacy of “on-demand” tramadol in patients with premature ejaculation: an updated meta-analysis
spellingShingle Safety and efficacy of “on-demand” tramadol in patients with premature ejaculation: an updated meta-analysis
Sharma,Aditya Prakash
Tramadol
Premature Ejaculation
Systematic Reviews as Topic
title_short Safety and efficacy of “on-demand” tramadol in patients with premature ejaculation: an updated meta-analysis
title_full Safety and efficacy of “on-demand” tramadol in patients with premature ejaculation: an updated meta-analysis
title_fullStr Safety and efficacy of “on-demand” tramadol in patients with premature ejaculation: an updated meta-analysis
title_full_unstemmed Safety and efficacy of “on-demand” tramadol in patients with premature ejaculation: an updated meta-analysis
title_sort Safety and efficacy of “on-demand” tramadol in patients with premature ejaculation: an updated meta-analysis
author Sharma,Aditya Prakash
author_facet Sharma,Aditya Prakash
Sharma,Gopal
Tyagi,Shantanu
Devana,Sudheer K.
Mavuduru,Ravimohan S.
Bora,Girdhar S.
Singh,Shrawan K.
author_role author
author2 Sharma,Gopal
Tyagi,Shantanu
Devana,Sudheer K.
Mavuduru,Ravimohan S.
Bora,Girdhar S.
Singh,Shrawan K.
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Sharma,Aditya Prakash
Sharma,Gopal
Tyagi,Shantanu
Devana,Sudheer K.
Mavuduru,Ravimohan S.
Bora,Girdhar S.
Singh,Shrawan K.
dc.subject.por.fl_str_mv Tramadol
Premature Ejaculation
Systematic Reviews as Topic
topic Tramadol
Premature Ejaculation
Systematic Reviews as Topic
description ABSTRACT Introduction: Tramadol has been used for the treatment of premature ejaculation, however, the studies published for the same are not well designed. The primary objective of this study was to explore the literature pertaining to the use of tramadol in patients with PE to determine its safety and efficacy in this population. Materials ande methods: Systematic literature search of various electronic databases was conducted to include all the randomized studies and quasi-randomized studies. Standard PRISMA (Preferred reporting Items for Systematic reviews and Meta-analysis) guidelines were pursued for this review and study protocol was registered with PROSPERO (CRD42019123381). Results: Out of 9 studies included in this review, 5 were randomized controlled trials, and rests of the 4 studies were quasi-randomized studies. Tramadol resulted in significantly higher improvement of IELT with the mean difference (MD) of 139.6 seconds and confidence interval (CI) 106.5-172.6 seconds with a p-value of p <0.00001. All dosages except 25mg fared well as compared to placebo. Tramadol fared better than placebo at 1 month, 2 months, and 3 months after initiation of therapy as compared to the placebo. Tramadol group had reported a significantly higher number of adverse events with treatment as compared to placebo but none of them were serious. Conclusion: Tramadol appears to be an effective drug for the management of PE with a low propensity for serious adverse events. However, evidence obtained from this study is of low to moderate quality. Furthermore, effective dose and duration of therapy remain elusive.
publishDate 2021
dc.date.none.fl_str_mv 2021-10-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382021000500921
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382021000500921
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/s1677-5538.ibju.2020.0561
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Urologia
publisher.none.fl_str_mv Sociedade Brasileira de Urologia
dc.source.none.fl_str_mv International braz j urol v.47 n.5 2021
reponame:International Braz J Urol (Online)
instname:Sociedade Brasileira de Urologia (SBU)
instacron:SBU
instname_str Sociedade Brasileira de Urologia (SBU)
instacron_str SBU
institution SBU
reponame_str International Braz J Urol (Online)
collection International Braz J Urol (Online)
repository.name.fl_str_mv International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)
repository.mail.fl_str_mv ||brazjurol@brazjurol.com.br
_version_ 1750318078109941760